GlassScriptPhysician profile
Ammar Alimam
NPI 1770542946
$1,059.15
in general payments reported to CMS, 2019-2025
14 companies · $57.04 in 2025
The $57.04 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $581 · 2020: $334 · 2021: $12.61 · 2022: $21.33 · 2023: $36.46 · 2024: $17.13 · 2025: $57.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $110.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $386.26 | 2019-2020 | |
| Genzyme Corporation | $182.05 | 2019-2020 | |
| United Therapeutics Corporation | $130.32 | 2019 | |
| Abbvie INC. | $102.38 | 2021-2025 | Dalvance |
| Regeneron Healthcare Solutions, INC. | $43.46 | 2019-2020 | |
| Philips North America LLC | $42.45 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $34.92 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.19 | 2019 | |
| Mylan Specialty L.P. | $24.31 | 2019 | |
| Angiodynamics, INC. | $21.33 | 2022 | |
| Acadia Pharmaceuticals INC | $20.86 | 2025 | Nuplazid |
| Genentech USA, INC. | $14.93 | 2019 | |
| Electromed, INC. | $14.48 | 2019 | |
| Insmed, INC. | $14.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ammar Alimam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.